Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > November 2008 - Volume 19 - Issue 6 > Immunosuppressive therapy for ocular diseases
Current Opinion in Ophthalmology:
doi: 10.1097/ICU.0b013e3283126d20
Ocular manifestations of systemic disease: Edited by Russell W. Read

Immunosuppressive therapy for ocular diseases

Jap, Alizaa,b; Chee, Soon-Phaikb,c,d

Collapse Box

Abstract

Purpose of review: To identify advances in immunosuppressive therapy of ocular diseases since 2007.

Recent findings: The biologics in current use include antitumour necrosis factor-α agents (infliximab, etanercept and adalimumab), cytokine receptor antibodies (daclizumab) and interferon-α2a. They are effective and comparatively well tolerated options in the treatment of refractory uveitis in both adults and children in the short term, except for etanercept. Daclizumab had a favourable outcome in treating birdshot chorioretinopathy but not in Behcet's disease. The uncertainty of their long-term results, their high costs as well as the necessity for repeated intravenous infusions in the case of infliximab limit their widespread use. Mycophenolate mofetil is another efficacious, fairly well tolerated and less costly immunosuppressant. It has the additional advantage of an oral formulation. T cell inhibitors, cyclosporine and tacrolimus, were found to be useful steroid-sparing drugs in allergic eye disease and dry eyes. A number of studies on less invasive sustained ocular drug delivery systems, including episcleral implants, nanospheres, and cyclodextrin particles, were conducted on animals with encouraging results.

Summary: The armamentarium of immunosuppressive agents is constantly expanding and augurs well for the safe and effective treatment of ocular inflammation.

© 2008 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.